Rehabilitating role of glutathione ester on cisplatin induced nephrotoxicity

Renal Failure

Volumn 21, Issue 2, 1999, Pages 209-217

  Babu, Ellappan ^a   Ebrahim, Abdul Shukkur ^a   Chandramohan, Natarajan ^a   Sakthisekaran, Dhanapal ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Cisplatin; Glutathione ester; Nephrotoxicity; Platinum

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GLUTATHIONE; PLATINUM DERIVATIVE;

ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID TUMOR;

EID: 0033003449     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229909066985     Document Type: Article

References (39)

1. Goldstein RS, Mayor GH: The nephrotoxicity of cisplatin. Life Sci 32:685-690, 1983.
2. Weiner MW, Jocobs C: Mechanism of cisplatin nephrotoxicity. Fed Proc 42:2974-2978, 1983.
3. Howell SB, Taetle R: The effect of sodium thiosulfate on cisdichlorodiammineplatinum (II) nephrotoxicity and antitumor activity in the L1210 leukemia. Cancer Treat Rep 64:611-616, 1980.
4. Hidaka S, Tsuruoka M, Funakoshi T, Shimada H, Kiyozumi M, Kojima S: Protective effects of dithiocarbamates against renal toxicity of cisdiamminedichloroplatinum in rats. Renal Failure 16:337-349, 1994.
5. Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O: Protective effect of reduced glutathione against cisplatin - induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interactions 70:89-101, 1989.
6. Sheikh - hamad D, Timmins K, Jalai Z: Cisplatin - induced renal toxicity: possible reversal by N-acetylcysteine treatment. J Am Soc Nephrol 8:1640-1645, 1997.
7. Basinger MA, Jones MM, Holscher MA: L-methionine suppresses pathological sequelae of cis-platinum in the rat. Fundam Appl Toxicol 14:568-577, 1990.
8. Babu E, Gopalakrishan VK, Navis Paul Sriganth I, Gopalakrishnan R, Sakthisekaran D: Cisplatin-induced nephrotoxicity and the modulating effect of glutathione ester. Mol Cell Biochem 144:7-11, 1995.
9. Martensson J, Meister A: Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester. Proc Natl Acad Sci 86: 471-475, 1989.
10. Anderson ME, Powrie F, Puri RN, Meister A: Glutathione monoester: preparation, uptake by tissues, and conversion to glutathione. Arch Biochem Biophys 239:538-548, 1985.
11. Dedon PC, Borch RF: Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 36:1955-1964, 1987.
12. Tedeschi M, Bohm S, DiRe F, Oriana S, Spatti GB, Tognella S, Zunino F: Glutathione and detoxification. Cancer Treat Rev 17:203-208, 1990.
13. Anderson ME, Naganuma A, Meister A: Protection against cisplatin toxicity by administration of glutathione ester. FASEB J 4:3251-3255, 1990.
14. Anderson ME, Meister A: Glutathione monoesters. Anal Biochem 183:16-20, 1989.
15. Sasaki T, Matsui S, Sanae A: Effect of acetic acid concentration on the color reaction in the O-toluidine -boric acid method of the blood glucose of determination. Rinsho Kagaku 1:346-353, 1972.
16. Natelson S, Scott ML, Beffa C: A rapid method for the estimation of urea in biologic fluids, by means of the reaction between diacetyl and urea. Am J Clin Pathol 21: 275-281, 1951.
17. Caraway WT: Uric acid. In: Seligson D (ed.); Standard methods of clinical chemistry. New York, Academic Press, 1963, pp 239-247.
18. Owen JA, Iggo B, Scandrett FJ, Stewart CP: The determination of creatinine in plasma or serum, and in urine; a critical examination. Biochem J 58:426-437, 1954.
19. King J: The hydrolases - add and alkaline phosphatases. In: King J (ed.); Practical Clinical Enzymology. London, Van D Nostrand Co, 1965, pp 191-208.
20. King J: The transferases - alanine and aspartate transaminases. In: King J, (ed.); Practical Clinical Enzymology. London, Van D Nostrand Co, 1965, pp 121-138.
21. Lowry OH, Rosebrough NJ, Fair AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
22. Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alock NW, Schwartz, MK, Young CW, Reidenberg MM: Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther 27:557-562, 1980.
23. Choie DD, Longnecker DS, Del Campo AA: Acute and chronic cisplatin nephrotoxicity in rats. Lab Invest 44(5):397-402, 1981.
24. Walker EM, Gale GR: Methods of reduction of cisplatin nephrotoxicity. Ann Clin Lab Sci 11:397-410, 1981.
25. Kim YK, Byun HS, Kim YH, Woo JS, Lee SH: Effect of cisplatin on renal function in rabbits: mechanism of reduced glucose reabsorption. Toxicol Appl Pharmacol 130:19-26, 1995.
26. Halabe A, Wong NLM, Sutton RAL: Effect of chronic cisplatin administration on phosphate and glucose transport by the renal brush border membrane. Nephron 57: 197-200, 1991.
27. Clarkson, TW: The pharmacology of mercury compounds. Annu Rev Pharmacol 12: 375-406, 1972.
28. Meister A: Metabolism and function of glutathione. In: Dolphin D, Poulson R, Avramovic O (eds); Glutathione: Chemical, Biochemical and Medical Aspects. Part A, New York, Wiley-Interscience, 1989, pp 367-474.
29. Reeves PG, Saari JT: Effect of cis-diamminedichloroplatinum (II) on metallothionein induction and trace element metabolism in rats fed different amounts of dietary zinc. J Nutr Biochem 1:374-381, 1990.
30. Safirstein R, Miller P, Dikman S, Lyman N, Shapiro C: Cisplatin nephrotoxicity in rats: defect in papillary hypertonicity. Am J Physiol 241:F175-F185, 1981.
31. Holmes EW, Kelley WN, Wyngaarden JB: The kidney and uric acid secretion in man. Kidney Int 2:115-121, 1972.
32. Nosaka K, Nakada J, Endou H: Cisplatin - induced alterations in renal structure, ammoniagenesis and gluconeogenesis of rats. Kidney Int 41:73-79, 1992.
33. Chopra S. Kaufman JS, Jones TW, Hong WK, Gehr MK, Hamburger RJ, Flamenbaum W, Trump BF: Cis-diamminedichloroplatinum-induced acute renal failure in the rat. Kidney Int 21:54-64, 1982.
34. t in the urine and kidney of the cisplatin treated rat. Toxicology 38:219-226, 1986.
35. Choie DD, Del Campo AA, Guarino AM: Subcellular localization of cis-dichlorodiammineplatinum (II) in rat kidney and liver. Toxicol Appl Pharmacol 55: 245-252, 1980.
36. Batzer MA, Aggarwal SK: An in vitro screening system for the nephrotoxicity of various platinum coordination complexes. A cytochemical study. Cancer Chemother Pharmacol 17:209-217, 1986.
37. Sadzuka Y, Shimizu Y, Takino Y, Hirota S: Protection against cisplatin -induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase. Biochem Pharmacol 48:453-459, 1994.
38. Treskes M, Boven E, Holwerda U, Pinedo HM, Van der Vijgh WJF: Time dependence of the selective modulation of cisplatin - induced nephrotoxicity by WR 2721 in the mouse. Cancer Res 52:2257-2260, 1992.
39. Bogin E, Marom M, Levi Y: Changes in serum, liver and kidneys of cisplatin-treated rats; effects of antioxidants. Eur J Clin Chem Clin Biochem 32:843-851, 1994.